Replies to post #2212 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

GTCB ReadMeFirst

[Updated for appointment of director from LFB.]


What is GTC’s business all about?
#msg-15159486 The business model in a single sentence!
#msg-9243634 Jan 2006 interview with CEO, Geoff Cox
#msg-9352093 2002 interview with Tom Newberry (dated, but informative)
#msg-13171505 “Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the more technical reader)
#msg-15638633 Musings on GTC’s business model (Dew)
#msg-14736913 3Q06 conference-call transcript


Valuation and finances
#msg- 15159486 Cash balance and share count
#msg-14509476 Cash usage and future financing
#msg-11409187 Rodman & Renshaw $4 target
#msg-11037571 Valuation comparator: MRK paid $400M for GlycoFi


Upcoming events
#msg-14575474 Clinical, preclinical goals in 2007-2008
#msg-14575754 Possible/probable news flow


BoD composition and insider shareholdings
#msg-15702541 Composition of Board of Directors
#msg-14730426 Current insider shareholdings


ATryn hereditary-deficiency program in Europe
#msg-11752181 Why ATryn?
#msg-11399356 ATryn approved by EMEA
#msg-11399033 ATryn Q&A from the EMEA
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-14545343 HD sales projection
http://www.atiii.com What is hereditary AT deficiency? (simple)
http://tinyurl.com/yb9hl5 What is hereditary AT deficiency? (technical)
http://tinyurl.com/yh8g2k Official product label


ATryn hereditary-deficiency program in U.S.
#msg-14545317 U.S. ATryn timeline
#msg-6543884 Non-availability of competing antithrombin
#msg-5607789 Efficacy endpoint is clinical DVT
#msg-5609005 Design of control arm
#msg-11410659 Likelihood of success
#msg-6632420 Patient eligibility and exclusions
#msg-11511614 Musings on a U.S. partnership


ATryn DIC/sepsis program in Europe
#msg-14363831 Rationale for pursuing DIC/sepsis indication
#msg-14516396 How sepsis causes DIC
#msg-12483101 Existing therapeutic options are weak
#msg-12480268 Surprising sepsis factoids
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-12511434 Phase-3 timeline
#msg-14495208 When will GTC receive milestone payments?
#msg-15305927 Design issues in the phase-2 trial


Miscellaneous info on ATryn and antithrombin
#msg-7306242 Which antithrombin will doctors prescribe?
#msg-4372780 Risks of plasma-derived proteins
#msg-13209941 Risks of plasma-derived proteins (addendum)
#msg-15535360 Risks of plasma-derived proteins (Mad Cow)
#msg-9502819 A patient’s story
#msg-15250714 Reference list of AT abstracts and articles


GTC-LFB program in Factor VIIa (and other therapies)
#msg-13731860 Who is LFB?
#msg-13956439 Who is LFB? (addendum)
#msg-13708619 Partnership terms
#msg-15247168 How the collaboration works
#msg-15036896 FVIIa sales projections
#msg-13763244 Patient pool for initial indication (hemophilia w/inhibitors)
#msg-13845005 Musings on LFB deal (by ‘chatalinda’)


NovoSeven (recombinant FVIIa from Novo-Nordisk)
NovoSeven website: http://www.novoseven-us.com
#msg-13980605 High price of NovoSeven (rationale for GTC-LFB program)
#msg-14084250 NovoSeven for acquired hemophilia
#msg-13925693 NovoSeven for trauma
#msg-14921693 NovoSeven (controversial) use in the military
#msg-13712057 Miscellaneous NovoSeven info


Miscellaneous research and development programs
Capsule summaries: http://www.transgenics.com/products/prod.html
#msg-14493025 Timeline of in-house and partnered programs
#msg-15170172 Background info on AAT deficiency
#msg-8163705 Merrimack program in RA
#msg-10727170 Merrimack program in psoriasis
#msg-14702182 Merrimack’s big plans for MM-093
#msg-14706678 Economics of GTC-Merrimack relationship
#msg-14714983 Musings on how MM-093 will be positioned
#msg-13797351 Grant for CD137 antibody program
#msg-7136629 Collaboration with Scancell
#msg-4316445 ATryn research contract with U.S. army


Intellectual property
#msg-9174865 Production (“milk”) patent
#msg-7179529 Purification patent
#msg-14493913 Pending patent applications
#msg-13154218 Nuclear-transfer IP from Geron
#msg-4107224 IP license to PharmAthene (formerly Nexia) for Protexia
#msg-14110344 Government grant for Protexia


Existing and potential competition
(See separate heading above for NovoSeven.)
#msg-7221666 Price and availability of commercial plasma-derived AT
#msg-14687679 Lovenox is not a competitor of ATryn
#msg-11909951 Thrombate AT from Talecris
#msg-14524596 Artisan Pharma thrombomodulin
#msg-14527640 Comments on Artisan’s program
#msg-15157973 Tifacogin for CAP/sepsis
#msg-14176380 AM-Pharma program in sepsis
#msg-14499024 AZN/Protherics program in sepsis
#msg-13763492 ‘Enhanced’ rFVIIa from Roche, Maxygen
#msg-15573025 Lipoxen/Baxter program in clotting factors
#msg-11829819 Talecris AAT
#msg-6488263 PurelyProteins AAT (market-size info)
#msg-14954548 Inhaled AAT from Kamada
#msg-13169472 GlycoFi/Merck (humanized yeast glycosylation)
#msg-13222976 More on the GlycoFi story
#msg-15116312 Biolex publication on homogeneity of glycosylation
#msg-10846766 Biolex Therapeutics (Locteron)
#msg-5919466 Biolex ‘plantibody’ patent
#msg-12155688 SemBioSys Genetics
#msg-14191540 Prairie Plant Systems
#msg-7542154 Origen’s transgenic chickens
#msg-8863527 Miscellaneous companies to watch


Feature stories on GTCB and transgenics
#msg-13365243 Times of London (9/06)
#msg-13152292 Nature.com (9/06)
#msg-14278650 Biotechnology Healthcare (8/06)
#msg-12573463 Nature Biotechnology (8/06)
#msg-12273566 Boston Globe profiles Dr. Harry Meade (7/06)
#msg-11635041 Framingham, Mass. Daily News (6/06)
#msg-9243634 Red Herring (1/06)
#msg-9143261 Business Week (1/06)
#msg-8162424 Scientific American (11/05)
#msg-6806806 Wall St Transcript interview with Tom Newberry (6/05)
#msg-6775592 Newsweek special issue on healthcare (6/05)
#msg-6276428 Worcester, MA Telegram & Gazette (5/05)
#msg-7431316 Nature Biotechnology (10/04)
#msg-4057315 The Economist (9/04)